What is a critical precaution when using biological therapies for SLE patients?

When considering the use of biological therapies for patients with systemic lupus erythematosus (SLE), monitoring for infections is a critical precaution. Biological therapies, such as monoclonal antibodies and other agents targeting specific components of the immune system, can significantly suppress the immune response. This immunosuppression increases the risk of infections, as the body's ability to fend off bacteria, viruses, and fungi is compromised.

Patients receiving these therapies are more susceptible to opportunistic infections, particularly those that a healthy immune system would typically control effectively. Therefore, regular monitoring for signs and symptoms of infections is essential. This includes vigilance for fever, respiratory issues, and urinary symptoms, among others. Early detection and management of infections can greatly improve outcomes and prevent severe complications in these patients.

While monitoring for improved joint function, weight gain, and sleep quality are all important aspects of comprehensive patient care, they do not directly address the heightened risk of infections associated with the immunosuppressive effects of biological therapies.